20-F: RedHill Biopharma Reports Financial Results for Year Ended December 31, 2024

Sentiment:

Annual Report 10 April 2025 7:36 AM

RedHill Biopharma releases its 20-F filing, highlighting financial results for the year ended December 31, 2024, and discussing strategic business transactions.

Capital raiseThe company states it will need to raise significant additional capital to achieve its strategic objectives and execute its business plans.The company plans to fund its future operations through commercialization of Talicia, out-licensing of its therapeutic candidates and commercialization of in-licensed or acquired products, and will also need to raise significant additional capital through equity or debt financing or non-dilutive financing, including government grants.The company is also actively pursuing and in discussions with multiple parties regarding strategic business transactions, which may provide it with additional capital.

Worse than expectedThe company reported a net loss of $8.3 million in 2024 compared to a net income of $23.9 million in 2023.The company's cash and cash equivalents decreased from $6.5 million in 2023 to $4.8 million in 2024.Management expresses substantial doubt about the company's ability to continue as a going concern.

Summary

RedHill Biopharma Ltd. has released its Form 20-F, detailing the financial results for the year ended December 31, 2024.
The company's net loss for 2024 was approximately $8.3 million, compared to a net income of approximately $23.9 million in 2023.
As of December 31, 2024, RedHill had cash, cash equivalents, short-term investments, and restricted cash of approximately $4.8 million.
The company is actively pursuing strategic business transactions to strengthen its balance sheet.
RedHill is focused on advancing its pipeline of therapeutic candidates and commercializing Talicia.
Management expresses substantial doubt about the company's ability to continue as a going concern without additional financing.
The company's internal control over financial reporting was deemed not effective as of December 31, 2024.
RedHill is working to remediate a material weakness related to the calculation of allowance for deductions from revenues.
The company is actively pursuing and in discussions with multiple parties regarding strategic business transactions.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are some positive developments, such as increased Talicia revenue and strategic partnerships, the overall sentiment is negative due to the net loss, going concern warning, and ineffective internal controls.

Positives

Talicia net revenues for the year ended December 31, 2024, increased to $9.0 million from $8.8 million for the year ended December 31, 2023, driven by approximately $1.0 million of revenues generated from the UAE partnership with Gaelan Medical.
The company is actively pursuing and in discussions with multiple parties regarding strategic business transactions.

Negatives

The company's net loss for 2024 was approximately $8.3 million, compared to a net income of approximately $23.9 million in 2023.
As of December 31, 2024, the company had cash, cash equivalents, short-term investments, and restricted cash of approximately $4.8 million.
Management expresses substantial doubt about the company's ability to continue as a going concern without additional financing.
The company's internal control over financial reporting was deemed not effective as of December 31, 2024.
A material weakness related to the calculation of allowance for deductions from revenues has not yet been fully remediated.

Risks

The company's financial statements include a going concern reference.
Failure to raise sufficient capital or conclude strategic business transactions may lead to ceasing operations.
The company's current working capital is not sufficient to commercialize Talicia or complete research and development.
Failure to maintain an effective system of internal control over financial reporting could harm the company's business and stock price.
The company may not successfully continue the commercialization of Talicia.
Failure to regain and maintain compliance with Nasdaq's continued listing requirements could result in delisting of the ADSs.

Future Outlook

The company plans to fund future operations through commercialization and out-licensing of therapeutic candidates, commercialization of in-licensed or acquired products, and raising additional capital.

Industry Context

The pharmaceutical and biotechnology industry is highly competitive, with RedHill facing competition from companies with greater resources and experience.

Comparison to Industry Standards

The document does not provide a direct comparison to industry standards.
It does mention competitors such as Juvis Pharmaceuticals and Phathom Pharmaceuticals, but does not provide a detailed comparison of results.
The document does not provide a direct comparison to industry standards.

Legal Proceedings

The company is involved in a lawsuit against Kukbo Co. Ltd. related to a defaulted subscription agreement and exclusive license agreement.
The company was awarded a judgment of approximately $8 million in the case, but Kukbo has filed a notice of appeal.

Stakeholder Impact

Shareholders face the risk of dilution from future equity offerings.
Shareholders could lose confidence in the company due to ineffective internal controls.
Employees may be affected by potential cost-reduction measures or changes in business operations.
The company's ability to serve patients depends on successful commercialization and regulatory approvals.

Next Steps

Continue commercialization of Talicia.
Advance the development of therapeutic candidates.
Pursue strategic business transactions.
Raise additional capital through various financing methods.
Remediate the material weakness in internal control over financial reporting.

Key Dates

Date	Description
2009-08-03	RedHill Biopharma Ltd. was incorporated.
2010-08-11	RedHill entered into an asset purchase agreement with Giaconda Limited.
2011-02	RedHill completed its initial public offering in Israel.
2012-12-27	RedHill completed the listing of ADSs on Nasdaq.
2014-06-30	RedHill entered into an exclusive license agreement with Wilex AG for RHB-107.
2015-03-30	RedHill entered into an exclusive worldwide license agreement with Apogee Biotechnology Corporation for opaganib.
2017-01-19	RedHill Biopharma Inc., a wholly-owned subsidiary, was incorporated in Delaware.
2018-07-20	The ADSs were listed on the Nasdaq Global Market.
2019-11-01	Talicia was approved by the FDA for marketing in the U.S.
2020-02-23	RedHill U.S. entered into a credit agreement with HCRM.
2020-03	RedHill launched Talicia in the U.S.
2020-07-01	RedHill Inc. entered into a new agreement with Daiichi Sankyo Inc.
2023-02-02	RedHill sold its rights in Movantik to an affiliate of HCRM.
2024-03-11	RedHill received a letter from Nasdaq indicating non-compliance with minimum bid price requirement.
2024-03-21	Shareholders approved the increase of authorized share capital.
2024-08-20	RedHill implemented a ratio change of the ADSs to ordinary shares.
2024-09-03	RedHill regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
2025-02-25	RedHill entered into an exclusive worldwide development and commercialization licensing agreement with Hyloris for RHB-102 (Bekinda).
2025-04-08	Representative rate of exchange as of this date ($1 = NIS 3.766).
2025-05-05	Scheduled annual general shareholder meeting to vote on the approval of an amended version of our compensation policy.

Keywords

RedHill Biopharma, financial results, 20-F filing, Talicia, strategic transactions, going concern, internal control, opaganib, RHB-107

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.